Lund University, Lund, Sweden

Section of Neurobiology, Department of Physiological Sciences

[Group description | Scientific staff | Publications within DiMI]

References

  1. Kirik D, Annett LE, Burger C, Muzyczka N, Mandel RJ, Bjorklund A. Nigrostriatal alpha-synucleinopathy induced by viral vector-mediated overexpression of human alpha-synuclein: a new primate model of Parkinson's disease. Proc Natl Acad Sci U S A, 2003. 100(5): p. 2884-9.
  2. Kirik D, Bjorklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends Neurosci, 2003. 26(7): p. 386-92.
  3. Bjorklund A, Dunnett SB, Brundin P, Stoessl AJ, Freed CR, Breeze RE, Levivier M, Peschanski M, Studer L, Barker R., Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol, 2003. 2(7): p. 437-45.
  4. Parmar, M, Skogh C, Bjorklund A, Campbell K. Regional specification of neurosphere cultures derived from subregions of the embryonic telencephalon. Mol Cell Neurosci, 2002. 21(4): p. 645-56.
  5. Kirik, D., et al., Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci U S A, 2002. 99(7): p. 4708-13.
  6. Kirik, D., et al., Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci, 2002. 22(7): p. 2780-91.
  7. Englund, U., et al., Grafted neural stem cells develop into functional pyramidal neurons and integrate into host cortical circuitry. Proc Natl Acad Sci U S A, 2002. 99(26): p. 17089-94.
  8. Kirik, D., C. Winkler, and A. Bjorklund, Growth and functional efficacy of intrastriatal nigral transplants depend on the extent of nigrostriatal degeneration. J Neurosci, 2001. 21(8): p. 2889-96.
  9. Dunnett, S.B., A. Bjorklund, and O. Lindvall, Cell therapy in Parkinson's disease - stop or go? Nat Rev Neurosci, 2001. 2(5): p. 365-9.
  10. Brundin, P., et al., Transplanted dopaminergic neurons: more or less? Nat Med, 2001. 7(5): p. 512-3.
  11. Piccini, P., et al., Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol, 2000. 48(5): p. 689-95.
  12. Lindvall, O. and A. Bjorklund, First step towards cell therapy for Huntington's disease. Lancet, 2000. 356(9246): p. 1945-6.
  13. Lee, C.S., et al., Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain, 2000. 123 ( Pt 7): p. 1365-79.
  14. Kirik, D., et al., Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci, 2000. 20(12): p. 4686-700.
  15. Brundin, P., et al., Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain, 2000. 123 ( Pt 7): p. 1380-90.
  16. Bjorklund, A. and O. Lindvall, Cell replacement therapies for central nervous system disorders. Nat Neurosci, 2000. 3(6): p. 537-44.
  17. Bjorklund, A. and O. Lindvall, Self-repair in the brain. Nature, 2000. 405(6789): p. 892-3, 895.
  18. Bjorklund, A. and O. Lindvall, Parkinson disease gene therapy moves toward the clinic. Nat Med, 2000. 6(11): p. 1207-8.